Welcome to our dedicated page for Corbus Pharmaceu news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceu stock.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage biopharmaceutical company advancing targeted therapies in precision oncology and metabolic disorders. This page serves as the definitive source for CRBP news, offering investors and researchers timely updates on scientific advancements and corporate developments.
Access verified information on clinical trial progress, regulatory milestones, and strategic partnerships across CRBP's pipeline. Key focus areas include Nectin-4 targeting antibody-drug conjugates, TGFβ pathway inhibitors, and novel obesity treatments designed to address critical unmet medical needs.
Our curated news collection enables efficient tracking of CRBP's innovative approaches to drug development. Stay informed about emerging data from studies evaluating CRB-701 in solid tumors, CRB-601's impact on tumor microenvironments, and CRB-913's potential in weight management.
Bookmark this page for direct access to official press releases and third-party analyses. Regular updates ensure you maintain current awareness of CRBP's position at the forefront of precision medicine development.
Corbus Pharmaceuticals (NASDAQ: CRBP) reported Phase 1a single- and multiple-ascending dose results for oral CB1 inverse agonist CRB-913 in obesity on Dec 11, 2025. The study (SAD n=64; MAD n=48) showed no serious treatment-emergent adverse events, minimal GI effects, and stable daily neuropsychiatric assessments (CSSRS, PHQ-9, GAD-7). In a dedicated obese MAD cohort (150 mg QD, n=12), all 9 treated participants lost weight vs 0/3 placebo, with a placebo-adjusted mean weight loss of 2.9% at Day 14 (individual range 1.3%–4.3%). PK supported once-daily oral dosing. A 12-week Phase 1b dose-finding study (CANYON-1) has been initiated, with completion expected in summer 2026. The company will host a conference call and webcast today at 8:00 am ET.
Corbus Pharmaceuticals (NASDAQ: CRBP) will release results from its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of oral CB1 inverse agonist CRB-913 before market open on Thursday, December 11, 2025.
The company will host a conference call and live webcast at 8:00 am ET the same day to review the Phase 1a safety and tolerability data; a replay will be available on the Corbus website.
Corbus Pharmaceuticals (NASDAQ: CRBP) reported Q3 2025 results and a corporate update on Nov 12, 2025. The company presented CRB-701 dose-optimization data at ESMO 2025 showing ORRs at 3.6 mg/kg of 47.6% in HNSCC, 37.5% in cervical cancer, and 55.6% in bladder cancer. Corbus plans an FDA meeting in Q1 2026 and expects to start a Phase 2/3 registrational study by mid-2026; CRB-701 has Fast Track designation for HNSCC and metastatic cervical cancer.
The company closed a public offering raising net proceeds of approximately $73.8M (total offering $75M), reporting $104.0M cash on 9/30/25 and stating runway into 2028. CRB-913 SAD/MAD readout and Phase 1b start expected by end of 2025. Q3 net loss was $23.3M versus $13.8M a year earlier.
Corbus Pharmaceuticals (Nasdaq: CRBP) will participate in three investor conferences in November–December 2025 with presentations and one-on-one meetings.
Schedule: Guggenheim Healthcare Innovation Conference in Boston on Nov 12, 2025 at 1:00 PM ET; Jefferies Global Healthcare Conference in London on Nov 18, 2025 at 4:00 PM GMT; Evercore 8th Annual Healthcare Conference in Miami on Dec 2, 2025 at 3:50 PM ET. Each event will offer a webcast (links provided by the company).
Corbus Pharmaceuticals (Nasdaq: CRBP) priced an underwritten public offering to raise approximately $75 million before underwriting discounts and expenses. The offering consists of 4,744,231 shares of common stock and pre-funded warrants to purchase 1,025,000 shares at $12.9999 each, with an exercise price of $0.0001 per share. Underwriters have a 30-day option for up to 865,384 additional shares. Closing is expected on or about November 3, 2025. Proceeds are intended to fund clinical development, working capital, and general corporate purposes.
Corbus Pharmaceuticals (Nasdaq: CRBP) announced on Oct 30, 2025 a proposed underwritten public offering of its common stock and, for certain investors, pre-funded warrants to purchase common stock. All securities will be sold by Corbus, and the offering is subject to market conditions with no assurance of completion, size, or terms.
Corbus said it intends to use net proceeds to fund clinical development of its pipeline and for working capital and general corporate purposes. Jefferies and Piper Sandler are joint book-running managers, and underwriters may receive a 30-day option to buy up to an additional 15% of the shares. A registration statement became effective on Mar 20, 2024.
Corbus Pharmaceuticals (NASDAQ: CRBP) reported Phase 1/2 CRB-701 (SYS6002) data presented at ESMO25 showing clinical activity and a manageable safety profile.
In response-evaluable patients dosed at 3.6 mg/kg, CRB-701 produced ORR 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in metastatic urothelial cancer. No dose-limiting toxicities were observed; Grade 3 treatment-related adverse events occurred in 18.0%, with no Grade 4/5 events and a 6.0% discontinuation rate. Data cutoff was September 1, 2025 (167 patients enrolled; 84 response-evaluable). The company plans an FDA meeting in 2025 and expects to initiate registrational studies by mid-2026.
Corbus Pharmaceuticals (NASDAQ: CRBP) will present updated Phase 1/2 data for CRB-701 (SYS6002) at ESMO 2025 on October 19, 2025 (Poster #967P) with a poster session from 12:00–12:45 CEST. The poster reports a September 1, 2025 data cut showing 167 enrolled participants, of which 122 were evaluable for efficacy across HNSCC (n=41), cervical (n=37), metastatic urothelial (n=23) and other dose-escalation tumors (n=21).
The abstract also includes safety data from an April 2025 cut on 70 participants. Corbus will host an in-person and virtual HNSCC KOL event in Berlin on October 19 at 10:00 CEST featuring HNSCC experts and a live Q&A.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D. will participate in a Fireside Chat at the Piper Sandler Virtual Oncology Symposium on October 9-10, 2025. The Corbus session is scheduled for October 9, 2025 at 10:00AM ET and will be hosted by Biren Amin, Managing Director, Piper Sandler Healthcare Equity Research.
Piper Sandler clients can register through their representative. The participation is a presentation event and does not include new financial guidance or clinical readout details.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced it will host a Key Opinion Leader (KOL) event at ESMO Congress 2025 in Berlin, Germany. The event will present dose optimization data from the Phase 1/2 clinical study of CRB-701 involving over 100 patients with head and neck squamous cell carcinoma (HNSCC), cervical, or metastatic urothelial tumors.
The KOL panel will feature prominent experts from leading institutions including the University of Chicago, Dana-Farber Cancer Institute, and Sarah Cannon Research Institute. The event is scheduled for October 19, 2025, at 10AM CEST, with both in-person and virtual attendance options available. The clinical trial data will also be presented as a poster at ESMO 2025.
FAQ
What is the current stock price of Corbus Pharmaceu (CRBP)?
What is the market cap of Corbus Pharmaceu (CRBP)?
